Aleksandar Sekulic was named director of dermatology and director of translational research at City of Hope Cancer Center Phoenix. Sekulic was also hired as a professor in the Integrated Cancer Genomics Division at Translational Genomics Research Institute, also called TGen.
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
